EyePoint (EYPT) Non Operating Investment Income (2011 - 2017)
EyePoint (EYPT) posted Non Operating Investment Income of $1000.0 for Q1 2017, little changed sequentially from $1000.0 in Q3 2016, and down 88.89% YoY from $9000.0 in Q1 2016.
Powered by 
Analysis
EyePoint (EYPT) Non Operating Investment Income (2011 - 2017) Analysis & Trends
EyePoint has reported Non Operating Investment Income for 7 years, with the latest figure at $1000.0 in Q1 2017.
- Quarterly Non Operating Investment Income fell 88.89% year-over-year to $1000.0 in Q1 2017, while the trailing twelve-month figure through Dec 2016 was $8000.0 (up 366.67% YoY) and the FY2016 annual result came in at $3000.0, up 175.0% from the prior year.
- Non Operating Investment Income held at $1000.0 in Q1 2017 per EYPT's latest filing, from $1000.0 in the prior quarter.
- Over five years, Non Operating Investment Income peaked at $9000.0 in Q1 2016 and troughed at -$6000.0 in Q4 2015.
- A 5-year average of $416.67 and a median of $1000.0 in 2014 frame the typical range for Non Operating Investment Income.
- The sharpest annual moves came in 2015 and 2016: Non Operating Investment Income plunged 200.0% in 2015, then jumped 800.0% in 2016.
- Over 5 years, Non Operating Investment Income stood at $4000.0 in 2013, then slumped by 150.0% to -$2000.0 in 2014, then slumped by 200.0% to -$6000.0 in 2015, then soared by 116.67% to $1000.0 in 2016, then changed by 0.0% to $1000.0 in 2017.
- According to Business Quant data, Non Operating Investment Income over the past three periods registered $1000.0, $1000.0, and -$2000.0 for Q1 2017, Q3 2016, and Q2 2016 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2017 | 1,000.00 |
| Sep 30, 2016 | 1,000.00 |
| Jun 30, 2016 | -2,000.00 |
| Mar 31, 2016 | 9,000.00 |
| Dec 31, 2015 | -6,000.00 |
| Sep 30, 2015 | 2,000.00 |
| Mar 31, 2015 | 1,000.00 |
| Dec 31, 2014 | -2,000.00 |
| Sep 30, 2014 | -3,000.00 |
| Jun 30, 2014 | 1,000.00 |
| Mar 31, 2014 | -1,000.00 |
| Jun 30, 2013 | 4,000.00 |
| Dec 31, 2012 | -5,000.00 |
| Sep 30, 2012 | 8,000.00 |
| Jun 30, 2012 | -4,000.00 |
| Mar 31, 2012 | 4,000.00 |
| Dec 31, 2011 | 7,000.00 |
| Sep 30, 2011 | -2,000.00 |